• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

sandoz

Sandoz announces in-licensing of Kindeva respiratory inhalation aerosol

March 17, 2021 By Sean Whooley

Sandoz Kindeva Drug Delivery

Sandoz announced that it is in-licensing the commercial distribution rights to a respiratory inhalation medicine from Kindeva Drug Delivery. Princeton, N.J.-based Sandoz in-licensed the rights to the brand and authorized generic of Proventil HFDA (albuterol sulfate) inhalation aerosol, which is immediately available to U.S. patients, according to a news release. Albuterol sulfate is used to […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Kindeva Drug Delivery, sandoz

Novartis unit spikes Pear Therapeutics deal

October 17, 2019 By Sean Whooley

Pear Therapeutics

Novartis (NYSE:NVS) unit Sandoz said this week that Pear Therapeutics will take sole responsibility for the commercialization of their prescription digital therapeutics program for treating substance and opioid use disorders. In April 2018, Pear announced that it agreed to deal commercialization rights of its digital therapeutics to Sandoz. The companies did not disclose financial details, but […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals Tagged With: Novartis, peartherapeutics, sandoz

Smiths Medical, United Therapeutics conspired to stifle generic Remodulin, Sandoz alleges

April 19, 2019 By Brad Perriello

gavel

Smiths Medical allegedly conspired with United Therapeutics to stifle a generic version of pulmonary arterial hypertension drug Remodulin, according to a lawsuit filed this week by Novartis (NYSE:NVS) unit Sandoz. The  Smiths Group (LON:SMIN) subsidiary, which is slated for a spinout as a separately traded company next year, makes the infusion pumps and single-use cartridges for […]

Filed Under: Featured, Legal News Tagged With: Novartis, sandoz, Smiths Group, Smiths Medical, United Therapeutics

Sandoz launches PFS alternative to epinephrine auto-injector

January 17, 2019 By Sarah Faulkner

Novartis' Sandoz division

Novartis (NYSE:NVS) division Sandoz said today that it launched its Symjepi epinephrine pre-filled syringe in the U.S. The company’s product is designed as an alternative to epinephrine auto-injectors to treat emergency allergic reactions. Sandoz described Symjepi as an “affordable” alternative to EpiPens but did not disclose the product’s price. “The Symjepi device is small in size and […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Novartis, sandoz

Sandoz, Pear launch digital therapy for opioid use disorder

January 8, 2019 By Sarah Faulkner

Pear Therapeutics logo updated

Novartis (NYSE:NVS) division Sandoz and Pear Therapeutics this week kicked off the U.S. commercial launch of the first FDA-cleared prescription digital therapy for people with opioid use disorder. The companies partnered to commercialize a 12-week cognitive behavioral therapy intended to be used in tandem with outpatient treatment. The therapy includes transmucosal buprenorphine and contingency management designed to reinforce […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals Tagged With: peartherapeutics, sandoz

Novartis steps in to compete with Mylan’s Epipen

July 2, 2018 By Sarah Faulkner

Adamis Pharmaceuticals

Adamis Pharmaceuticals (NSDQ:ADMP) said this week that it inked an exclusive deal with Novartis‘ (NYSE:NVS) Sandoz unit to distribute and commercialize its Symjepi emergency allergy treatment. The agreement puts Novartis in the position to compete directly with Mylan‘s (NSDQ:MYL) EpiPen auto-injector. The pharma giant has been under pressure in recent months thanks to manufacturing delays that have […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: adamispharmaceuticals, Novartis, sandoz

Pear Therapeutics, Sandoz ink deal for prescription digital therapeutics

April 19, 2018 By Sarah Faulkner

Pear Therapeutics

Pear Therapeutics revealed yesterday that it agreed to deal commercialization rights of its digital therapeutics to Novartis (NYSE:NVS) division Sandoz. The company’s reSET substance use disorder therapy became the first prescription digital therapeutic approved by the FDA in September last year. reSET-O, a digital therapeutic designed for people suffering from opioid use disorder, is under review […]

Filed Under: Business/Financial News, Featured, mHealth (Mobile Health), Patient Monitoring, Wall Street Beat Tagged With: Novartis, peartherapeutics, sandoz

Sandoz wins FDA nod for generic, injectable MS drug

February 13, 2018 By Sarah Faulkner

Sandoz

Sandoz said today that the FDA has approved its Glatopa glatiramer acetate injection as a generic version of Copaxone to treat relapsing forms of multiple sclerosis. The therapy, which is given three days per week, is administered using the Glatopaject injection device. The 20 mg/mL version of the MS treatment has been available in the […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Novartis, sandoz

FDA rejects Novartis’ Advair generic, leaving GSK without rival

February 8, 2018 By Sarah Faulkner

GlaxoSmithKline

GlaxoSmithKline (NYSE:GSK) was granted a temporary win today after Novartis‘ (NYSE:NVS) Sandoz unit reported that the FDA rejected its application for a generic version of the company’s blockbuster lung treatment, Advair. The regulatory agency reportedly told Novartis that it needs to submit additional clinical data before the FDA can make its final decision. GSK said in […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Novartis, sandoz

Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus

June 16, 2017 By Sarah Faulkner

Novartis

Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus. The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Amgen, Novartis, sandoz

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS